A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 38,061 shares of ATXS stock, worth $367,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,061
Previous 22,461 69.45%
Holding current value
$367,288
Previous $204,000 105.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.97 - $12.65 $139,932 - $197,340
15,600 Added 69.45%
38,061 $419,000
Q2 2024

Aug 09, 2024

SELL
$8.83 - $13.51 $167,231 - $255,865
-18,939 Reduced 45.75%
22,461 $204,000
Q1 2024

May 13, 2024

BUY
$6.99 - $16.69 $190,128 - $453,968
27,200 Added 191.55%
41,400 $583,000
Q4 2023

Feb 13, 2024

BUY
$4.42 - $8.06 $18,122 - $33,046
4,100 Added 40.59%
14,200 $109,000
Q3 2023

Nov 14, 2023

SELL
$6.89 - $9.86 $557,821 - $798,275
-80,961 Reduced 88.91%
10,100 $75,000
Q2 2023

Aug 11, 2023

BUY
$8.33 - $13.72 $356,199 - $586,680
42,761 Added 88.53%
91,061 $759,000
Q1 2023

May 12, 2023

SELL
$11.2 - $15.79 $380,363 - $536,244
-33,961 Reduced 41.28%
48,300 $642,000
Q4 2022

Feb 13, 2023

BUY
$7.44 - $14.89 $181,536 - $363,316
24,400 Added 42.17%
82,261 $1.23 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $131,158 - $456,624
44,161 Added 322.34%
57,861 $523,000
Q2 2022

Aug 12, 2022

BUY
$2.46 - $6.96 $33,702 - $95,352
13,700 New
13,700 $41,000
Q1 2022

May 13, 2022

SELL
$3.92 - $7.1 $134,695 - $243,963
-34,361 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$5.08 - $8.62 $380,959 - $646,431
-74,992 Reduced 68.58%
34,361 $185,000
Q3 2021

Nov 12, 2021

BUY
$7.32 - $12.9 $800,463 - $1.41 Million
109,353 New
109,353 $967,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $146M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.